Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P52742 (pT3)
 1,034 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Our experience of radical nephrectomy was analyzed and recent management of renal cell carcinoma was reviewed. One hundred forty-eight patients with renal cell carcinoma were treated by radical nephrectomy between 1970 and December, 1986. The 5-year survival rate according to pathological T-stage was 100% for 4 patients in pT1, 73% for 85 patients in pT2, 51% for 54 patients in pT3, and 0% for 5 patients in pT4. Four patients in pT1 had no venous involvement, lymph node metastasis, or distant metastasis. Thirty patients had venous involvement, 8 in pT2, 20 in pT3 and 2 in pT4. Seventeen patients had positive lymph nodes, 0 in pT2, 15 in pT3 and 2 in pT4. Thirty-three patients had distant metastasis at the time of nephrectomy, 12 in pT2, 18 in pT3 and 3 in pT4. The 5-year survival rates of 30 patients with venous involvement, 17 with lymph node metastasis and 33 with distant metastasis were 47%, 30% and 37%, respectively. No anti-cancer drugs have been recognized to be effective for renal cell carcinoma. However, recent experiences with interferon and lymphokine-activated killer cell therapy suggest that immunotherapy may have a potential role in the management of metastatic renal cell carcinoma.
 ...
PMID:[Recent management of renal cell carcinoma]. 325 77

Five-year overall survival after radical surgery in N0M0 renal cell carcinoma varies from 45-80% in pT2 to 35-50% in pT3 categories. In view of the alpha interferon and vinblastine combination which has shown some activity in advanced disease with increasing efficacy in limited metastatic invasion, we decided to explore the theoretical advantage of adjuvant chemo-immunotherapy in radically resected stage II, III renal cell carcinoma. A single-institution phase II study was undertaken to evaluate the efficacy and tolerability of alpha 2a-interferon (alpha 2a-INF) in combination with vinblastine in 30 patients with pT2-T3 N0M0 renal cell carcinoma (RCC). Thirty-two patients who received only radical nephrectomy and extended lymphadenectomy were analyzed and results were compared with the first group. Twenty-three of 30 (76.6%) patients in the first group are alive with no evidence of disease. The median follow-up for the 23 patients still alive was 67 months (range 60 to 72). Metastases were documented in 5 patients (16.6%) with a median interval to progression of 24 months. Four of them (13.6%) died of tumor. In the control group, 16 out of 32 patients (50%) are still alive, with a median follow-up for the patients still alive of 62 months (range 60 to 68). Fifteen patients developed distant metastases and 2 of them had a local recurrence. All of them (46.8%) died of tumor. Median progression interval was 24 months. After stratification by pathological grade, site, laterality and number of nodes found at lymphadenectomy there were no statistical differences in risk of progression or death in the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma? 756 21

Because the primary aim of adjuvant therapy for melanoma is not curative, all the possible aspects of quality of life have to be considered. One aspect of increasing importance is fertility. The effect of adjuvant interferon alpha-therapy for malignant melanoma on male fertility has not been systematically investigated. In the present study, twelve male patients with primary cutaneous melanoma (pT3, 4; N0; M0) who were taking adjuvant low-dose interferon alpha2b (3 x 3 mio U/week) for one year were included. Inhibin B--an established marker of male fertility-was measured with an immunosorbent assay before and after one year of interferon alpha-therapy to investigate whether this treatment has any influence on fertility. The results were compared with those from normal controls (n=40). The mean serum inhibin B concentration in melanoma patients before interferon therapy was 225.4 +/- 112.5 pg/mL; after treatment the level was 229.6 +/- 82.0 pg/mL. This difference was not statistically significant (p>0.05). The serum inhibin B concentration in controls was 201.5 +/- 17.1 pg/mL, which was not statistically different from either untreated or interferon-treated melanoma patients (p>0.05). We conclude that low-dose interferon alpha does not have a significant (negative) effect on inhibin B or male fertility.
 ...
PMID:Effects of adjuvant interferon-alpha low-dose therapy in melanoma patients on serum inhibin B. 1109 67